Ask Aeroz

Type the question you actually came here with.

EU FMD · Prescription medicines

The EU Falsified Medicines Directive, pack by pack.

The EU Falsified Medicines Directive (2011/62/EU) requires prescription medicines to carry a unique identifier and an anti-tampering device, checked against the European Medicines Verification System before each pack reaches a patient.

Since 9 February 2019, prescription medicines placed on the EU market carry two safety features: a unique identifier in a 2D Data Matrix code and an anti-tampering device. Manufacturers upload each pack's identifier to the European Hub, which feeds the national verification systems. Wholesalers verify the packs that carry more risk, and pharmacies and hospitals verify and decommission each pack before it reaches a patient. Italy and Greece, the last two member states, joined on 9 February 2025.

Directive 2011/62/EUReg. (EU) 2016/161Data MatrixEMVSIn force
Key facts · reviewed

EU Falsified Medicines Directive, in three facts.

Directive 2011/62/EU · Delegated Regulation (EU) 2016/161 · in application since 9 February 2019 · unique identifier + anti-tampering device · verified against the EMVS.

  • Since 9 February 2019 most prescription medicines in the EU carry a unique identifier in a Data Matrix code and an anti-tampering device.

    Source: Delegated Regulation (EU) 2016/161
  • Under Delegated Regulation (EU) 2016/161 the serial number in a medicine pack's unique identifier is a numeric or alphanumeric sequence of up to 20 characters from a randomisation algorithm, and the probability of guessing it must be lower than one in ten thousand.

    Source: Delegated Regulation (EU) 2016/161, Article 4 (text as adopted)
  • In the European Medicines Verification System, manufacturers upload each pack's unique identifier to the European Hub, which connects the national medicines verification systems where packs are verified.

    Source: EMVO, EMVS go-live announcement (8 February 2019)
What the rule requires

Two safety features, one shared system.

A unique identifier on every pack

The manufacturer encodes a product code, a serial number, the batch number and the expiry date, plus a national reimbursement number where a member state requires one, in a 2D Data Matrix. The serial is randomised, up to 20 characters, with a chance of being guessed below one in ten thousand.

An anti-tampering device

Every pack also carries a device that shows whether it has been opened. Whoever verifies the identifier checks the device as well.

Uploaded to the European Hub

Manufacturers and parallel distributors upload each pack's identifier to the European Hub, run by the European Medicines Verification Organisation (EMVO). The hub passes the data to the national system of each market where the pack can be sold.

Checked at the end of the chain

Pharmacies verify the safety features and decommission the identifier when they supply the pack. Wholesalers verify the packs that carry more risk, such as returns, and hospitals can decommission at any time a pack is in their physical possession.

The dates

The timeline, as it stands.

The system went live across the EU on 9 February 2019. Belgium, Greece and Italy had a derogation because they already ran national systems; Belgium applied the EU rules from 2019 anyway, and Greece and Italy joined on 9 February 2025. Italy's transition for packs with its old stamp runs to 8 February 2027.

Safety features apply, EU-widesince 9 Feb 2019
Greece and Italy join the EU system9 Feb 2025
Italy's transition for stamped packs ends8 Feb 2027
What to do now

Three moves that de-risk the deadline.

01 · Step

Map every market a pack can reach

One pack can be sold in several member states. List which national systems each product's data must reach, and which ones need a national reimbursement number inside the code.

02 · Step

Plan for alerts, not just uploads

A failed scan raises an alert that the pharmacy, the wholesaler and the manufacturer all see. Decide who investigates, how fast, and where the evidence is kept.

03 · Step

Know what the code cannot prove

The Data Matrix proves a serial number is in the system and not yet used. If a code is copied, whichever pack is scanned first passes and the other raises an alert. Decide where you need a second, physical check.

How Aeroz fits

Alongside the EMVS, not instead of it.

Aeroz does not replace the European system or your serialisation line. It adds a physical identity to the pack or case that answers a tap with a signed response, so a wholesaler, a hospital or an investigator can tell the genuine pack from a copy of its code, and it keeps the custody record behind every alert in one place.

FAQ

EU Falsified Medicines Directive, answered.

What is the EU Falsified Medicines Directive?

Directive 2011/62/EU amended the EU medicines code to keep falsified medicines out of the legal supply chain. The detailed rules for the safety features on packs are in Delegated Regulation (EU) 2016/161, which has applied since 9 February 2019.

Which medicines need the safety features?

Prescription medicines, unless they are on the regulation's exemption list, and a short list of non-prescription medicines judged at risk of falsification. Member states can extend the scope for reimbursement or patient-safety reasons.

What is the EMVS?

The European Medicines Verification System: a European Hub run by EMVO, connected to a national medicines verification system in each market. Manufacturers and parallel distributors connect to the hub; wholesalers, pharmacies and hospitals connect to their national system.

What happens when a pack fails verification?

It is not supplied. The person who finds it informs the competent authorities, and the alert travels back through the hub to the company that uploaded the pack.

Does the FMD still apply in the UK?

No. The EU FMD safety features were disapplied across the UK from 1 January 2025, and UK packs now carry a 'UK Only' label. See the UK guide.

Readiness audit

Know exactly where you stand, in 14 days.

A fixed-fee Aeroz audit maps your products against the EU Falsified Medicines Directive safety features and your EMVS obligations and returns a written readiness assessment, a data-mapping review, and a scoped pilot plan with cost and timeline.

Fixed fee: Readiness Report $2,500, Readiness Audit $4,500 14-day written report No commitment to proceed